ECSP10010471A - Agonistas nicotínicos alfa 7 y antipsicóticos - Google Patents

Agonistas nicotínicos alfa 7 y antipsicóticos

Info

Publication number
ECSP10010471A
ECSP10010471A EC2010010471A ECSP10010471A ECSP10010471A EC SP10010471 A ECSP10010471 A EC SP10010471A EC 2010010471 A EC2010010471 A EC 2010010471A EC SP10010471 A ECSP10010471 A EC SP10010471A EC SP10010471 A ECSP10010471 A EC SP10010471A
Authority
EC
Ecuador
Prior art keywords
antipsychotic
alfa
nicotine agonists
nicotine
agonists
Prior art date
Application number
EC2010010471A
Other languages
English (en)
Spanish (es)
Inventor
Merouane Bencherif
Gregory J Gatto
Kristen G Jordan
Sharon R Letchworth
Terry Hauser
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of ECSP10010471A publication Critical patent/ECSP10010471A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
EC2010010471A 2008-02-13 2010-09-09 Agonistas nicotínicos alfa 7 y antipsicóticos ECSP10010471A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13

Publications (1)

Publication Number Publication Date
ECSP10010471A true ECSP10010471A (es) 2010-10-30

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010471A ECSP10010471A (es) 2008-02-13 2010-09-09 Agonistas nicotínicos alfa 7 y antipsicóticos

Country Status (25)

Country Link
US (1) US20110059947A1 (enExample)
EP (2) EP2633868A1 (enExample)
JP (1) JP2011511845A (enExample)
KR (1) KR20100113163A (enExample)
CN (2) CN101977628A (enExample)
AU (1) AU2009214625A1 (enExample)
BR (1) BRPI0907570A2 (enExample)
CA (1) CA2715268A1 (enExample)
CO (1) CO6290706A2 (enExample)
CY (1) CY1114492T1 (enExample)
DK (1) DK2254598T3 (enExample)
EC (1) ECSP10010471A (enExample)
ES (1) ES2430622T3 (enExample)
HR (1) HRP20130749T1 (enExample)
IL (1) IL207389A0 (enExample)
MX (1) MX2010008875A (enExample)
NZ (1) NZ587312A (enExample)
PL (1) PL2254598T3 (enExample)
PT (1) PT2254598E (enExample)
RS (1) RS52941B (enExample)
RU (1) RU2481123C2 (enExample)
SG (1) SG188144A1 (enExample)
SI (1) SI2254598T1 (enExample)
WO (1) WO2009102962A2 (enExample)
ZA (1) ZA201005999B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
AU2012207499A1 (en) * 2011-01-18 2013-08-15 Targacept, Inc. Treatment of cognitive dysfunction in schizophrenia
EP2704573A4 (en) * 2011-05-03 2014-10-15 Merck Sharp & Dohme AMINOMETHYL biaryl BENZOTRIAZOL DERIVATIVES
MX2015004285A (es) * 2012-10-02 2015-08-06 Sumitomo Dainippon Pharma Co Ltd Derivado de imidazol.
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN117480169A (zh) * 2021-01-08 2024-01-30 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
ATE255888T1 (de) 1998-06-01 2003-12-15 Ortho Mcneil Pharm Inc Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
CZ20021880A3 (cs) * 1999-12-10 2002-08-14 Wyeth Farmaceutický prostředek
IL153707A0 (en) * 2000-06-27 2003-07-06 S A L V A T Lab Sa Carbamates derived from arylalkylamines
AU2001282873A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
EP1311505A2 (en) 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
MXPA04008152A (es) * 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
MXPA05005943A (es) * 2002-12-06 2005-08-18 Pharmacia & Upjohn Co Llc Sales fumarato cristalinas de furo[2,3-c]piridinilcarboxamida sustituida con 1-azabiciclo[2.2.2]octilo y composiciones y preparaciones de las mismas.
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
CA2549638A1 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
WO2006101745A2 (en) * 2005-03-18 2006-09-28 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Also Published As

Publication number Publication date
DK2254598T3 (da) 2013-07-29
CN101977628A (zh) 2011-02-16
HRP20130749T1 (en) 2013-10-11
RS52941B (sr) 2014-02-28
PL2254598T3 (pl) 2013-12-31
BRPI0907570A2 (pt) 2019-09-24
RU2481123C2 (ru) 2013-05-10
NZ587312A (en) 2011-12-22
EP2254598A2 (en) 2010-12-01
ES2430622T3 (es) 2013-11-21
CY1114492T1 (el) 2016-10-05
MX2010008875A (es) 2010-08-31
CN103143023A (zh) 2013-06-12
ZA201005999B (en) 2011-05-25
KR20100113163A (ko) 2010-10-20
JP2011511845A (ja) 2011-04-14
EP2633868A1 (en) 2013-09-04
AU2009214625A1 (en) 2009-08-20
CA2715268A1 (en) 2009-08-20
RU2010137787A (ru) 2012-03-20
HK1147954A1 (en) 2011-08-26
CO6290706A2 (es) 2011-06-20
PT2254598E (pt) 2013-10-16
SG188144A1 (en) 2013-03-28
US20110059947A1 (en) 2011-03-10
WO2009102962A2 (en) 2009-08-20
EP2254598B1 (en) 2013-07-10
SI2254598T1 (sl) 2013-10-30
IL207389A0 (en) 2010-12-30
WO2009102962A3 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
ECSP10010471A (es) Agonistas nicotínicos alfa 7 y antipsicóticos
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
CL2010001428A1 (es) Compuestos derivados de amidas y tioamidas heteroaromaticas; agente que contiene al menos uno de dichos compuestos; procedimiento para combatir parasitos; y uso de dichos compuestos.
NI201100068A (es) Combinación de una insulina y un agonista de glp-1.
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
UY33397A (es) Forma sólida de un naftaleno carboxamida
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
MY156511A (en) Compositions and devices
MX2013007236A (es) Composiciones fluidas que comprenden un agente de estructuracion.
GT200800123A (es) Compuestos mimeticos de lisina modificados
EP2176769A4 (en) DELEGATE INSTANT MESSAGING MEETINGS
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
DOP2010000225A (es) Arilpirrolinas insecticidas
HN2008000278A (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion terapeutica
MX2012008717A (es) Composiciones para el cuidado oral.
BRPI0906424A2 (pt) recurso de atributo de cache extraído e instrução consequente
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EP2252671A4 (en) AZEOTROPARTIC COMPOSITION OF 1,1,1-TRIFLUOR-3-CHLOROPROPENE AND DIMETHOXYMETHANE
AR067813A1 (es) Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
CR20110227A (es) Partículas inhalables que comprenden tiotropio
CR20150275A (es) Composición de difenidol de liberación prolongada
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.